Study of T-DXd for advanced breast cancer with very low HER2
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests a drug called T-DXd (trastuzumab deruxtecan) for people with advanced breast cancer that has very low levels of HER2 (a protein that helps cancer grow) and that is also hormone receptor positive. The goal is to see if this drug can help shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- Your breast cancer has spread to other parts of the body (metastatic) or cannot be removed with surgery.
- Your cancer is hormone receptor positive (tests positive for estrogen or progesterone receptors).
- Your cancer was previously tested and found to have no HER2 protein (HER2-negative), but a newer test shows very low levels of HER2 (called HER2-ultralow).
- You have received at least one, but no more than two, previous hormone treatments for metastatic disease.
- You have not had more than one chemotherapy treatment for metastatic disease, and if you had chemotherapy, it was not the most recent treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows women with advanced breast cancer (metastatic) who have hormone-receptor positive tumors and low HER2 levels, to see how well a new drug called Trastuzumab Deruxtecan works when used in routine clinical care after prior hormone therapy.
This trial tests a targeted antibody-drug medicine (trastuzumab deruxtecan, T-DXd) in people with metastatic breast cancer that is HER2-low or HER2 IHC 0. It may help by treating tumors that haven’t previously received anti-HER2 treatment in the metastatic setting.
This study looks at how well Trastuzumab Deruxtecan (T-DXd) works in Chinese women with breast cancer that has spread. It is for people whose cancer is either HER2-positive or HER2-low and who have already had some treatment.
This study looks at how people feel (patient-reported outcomes) and their real-world health data while they receive trastuzumab deruxtecan for advanced HER2-positive, HER2-low, or HER2-ultralow breast cancer. It helps researchers understand what outcomes happen outside of tightly controlled clinical trials.
This trial compares a new drug called Trastuzumab-Deruxtecan (T-DXd) to standard treatment for people with early breast cancer whose cancer has come back at a molecular level (detected by a blood test) but hasn't spread to other parts of the body. The goal is to see if T-DXd can prevent the cancer from returning.
This study tests a combination of two targeted therapies—trastuzumab deruxtecan and pyrotinib—as a first treatment for HER2-positive breast cancer that has spread. The goal is to see if this combination helps shrink tumors or delay progression better than current options.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.